Switch theme
Sign up to access all valuation multiples
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
2020
220
LTM Revenue $3.2M
Last FY EBITDA -$132M
$366M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Humacyte has a last 12-month revenue (LTM) of $3.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Humacyte achieved revenue of n/a and an EBITDA of -$132M.
Humacyte expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Humacyte valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $2.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$132M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$104M | XXX | -$114M | XXX | XXX | XXX |
| EBIT Margin | -3244% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$98.5M | XXX | -$149M | XXX | XXX | XXX |
| Net Margin | -3082% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Humacyte's stock price is $3.
Humacyte has current market cap of $413M, and EV of $366M.
See Humacyte trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $366M | $413M | XXX | XXX | XXX | XXX | $-0.82 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Humacyte has market cap of $413M and EV of $366M.
Humacyte's trades at n/a EV/Revenue multiple, and -2.8x EV/EBITDA.
Equity research analysts estimate Humacyte's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Humacyte has a P/E ratio of -4.2x.
See valuation multiples for Humacyte and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $413M | XXX | $413M | XXX | XXX | XXX |
| EV (current) | $366M | XXX | $366M | XXX | XXX | XXX |
| EV/Revenue | 114.5x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.8x | XXX | XXX | XXX |
| EV/EBIT | -3.5x | XXX | -3.2x | XXX | XXX | XXX |
| EV/Gross Profit | 162.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.2x | XXX | -2.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHumacyte's last 12 month revenue growth is 987%
Humacyte's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
Humacyte's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Humacyte's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Humacyte and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 987% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Humacyte acquired XXX companies to date.
Last acquisition by Humacyte was XXXXXXXX, XXXXX XXXXX XXXXXX . Humacyte acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Humacyte founded? | Humacyte was founded in 2020. |
| Where is Humacyte headquartered? | Humacyte is headquartered in United States of America. |
| How many employees does Humacyte have? | As of today, Humacyte has 220 employees. |
| Who is the CEO of Humacyte? | Humacyte's CEO is Dr. Laura E. Niklason, M.D.,PhD. |
| Is Humacyte publicy listed? | Yes, Humacyte is a public company listed on NAS. |
| What is the stock symbol of Humacyte? | Humacyte trades under HUMA ticker. |
| When did Humacyte go public? | Humacyte went public in 2021. |
| Who are competitors of Humacyte? | Similar companies to Humacyte include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Humacyte? | Humacyte's current market cap is $413M |
| What is the current revenue of Humacyte? | Humacyte's last 12 months revenue is $3.2M. |
| What is the current revenue growth of Humacyte? | Humacyte revenue growth (NTM/LTM) is 987%. |
| What is the current EV/Revenue multiple of Humacyte? | Current revenue multiple of Humacyte is 114.5x. |
| Is Humacyte profitable? | Yes, Humacyte is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
